It surprises people every day: yes, GLP-1 telehealth platforms deny applications. A denial usually stings and confuses in equal measure — but each denial reason maps to a specific clinical or legal rule, and each has a different correct next step. Here's the taxonomy.
Key Takeaways
- A denial from one platform is that clinician's judgment on that day's information — it is not a permanent verdict, but it deserves understanding before you shop it.
- BMI below criteria, MTC/MEN2 history, pregnancy plans, active eating disorder, and pancreatitis history are the most common hard or soft stops.
- Some denials dissolve with more information (records, labs, specialist clearance); others are protecting you from a real risk.
- A platform that denies people demonstrably has clinicians exercising judgment — it's paradoxically a good sign about the ones they approve.
The Eligibility Denials
BMI below criteria. The standard indication is BMI 30+, or 27+ with a weight-related comorbidity (hypertension, prediabetes, sleep apnea, dyslipidemia). If you're at 27.5 with no documented comorbidity, the fix may literally be documentation — a recent blood pressure record or an A1C in the prediabetes range changes the picture. Honest platforms deny rather than fudge; be suspicious of any that coach you to misreport your weight.
The Contraindication Denials
Personal or family history of medullary thyroid carcinoma or MEN2. This is the boxed-warning contraindication and no legitimate prescriber will cross it. This denial is final everywhere, and that's the system working.
Pancreatitis history. A softer stop — some platforms decline categorically, others want records showing the cause and resolution. If your episode was, say, a resolved gallstone pancreatitis years ago, records and possibly a GI clearance letter can reopen the door at more thorough providers.
Pregnancy, trying, or breastfeeding. Categorical and universal; the medication is stopped before conception. The next step is a timeline conversation, not another application.
The Safety-Screen Denials
Active or recent eating disorder. Appetite suppressants layered on restrictive pathology are dangerous, and this denial is protective. The path forward, where one exists, runs through treatment and a specialist's involvement — not through a platform with weaker screening.
Medication interactions. Insulin or sulfonylurea regimens can require coordination the platform can't provide; complex psychiatric regimens sometimes trigger the same judgment. This denial often means "you need a prescriber who can manage the whole picture" — which may be your existing doctor plus a GLP-1, rather than a standalone platform.
The Non-Clinical Denials
State coverage. No licensed clinician in your state, or state rules incompatible with the platform's visit model. Nothing about you — try a platform with different state coverage.
Identity or age verification failure. Fix the document issue and reapply.
If You Believe the Denial Was Wrong
Reply through the portal and ask for the specific reason — legitimate platforms tell you. Provide the missing information if it exists. And if you shop for a second opinion, shop up the quality ladder, not down it: the goal is a more thorough review, not a blinder one.
Enhance MD
Injectable GLP-1 program
Established telehealth clinic with injectable GLP-1 protocols and live provider access.
Compounded medications are not FDA-approved.
Visit Enhance MD Paid linkSesame Care
Brand-name only — Rybelsus and oral Wegovy from $149–$299/mo
Brand-name FDA-approved medications only through a transparent marketplace — no compounded products.
Visit Sesame Care Paid linkAffiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.